ZHB A007
Alternative Names: ZHB-A007Latest Information Update: 29 Aug 2025
At a glance
- Originator Jiangsu ZonHon Biopharma Institute
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Food hypersensitivity
Most Recent Events
- 23 Jul 2025 Preclinical trials in Food hypersensitivity in China (unspecified route) before July 2025 (Jiangsu ZonHon Biopharma Institute pipeline, July 2025)